CanBas Co., Ltd. - Product Pipeline Review - 2014

Date: March 31, 2014
Pages: 29
Price:
US$ 1,500.00 US$ 1,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C7EF322A684EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘CanBas Co., Ltd. - Product Pipeline Review - 2014’, provides an overview of the CanBas Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CanBas Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of CanBas Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CanBas Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CanBas Co., Ltd.’s pipeline products
Reasons to buy
  • Evaluate CanBas Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CanBas Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CanBas Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CanBas Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CanBas Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CanBas Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
CanBas Co., Ltd. Snapshot
CanBas Co., Ltd. Overview
Key Information
Key Facts
CanBas Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
CanBas Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
CanBas Co., Ltd. - Pipeline Products Glance
CanBas Co., Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CanBas Co., Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
CanBas Co., Ltd. - Drug Profiles
CBP-501 + [cisplatin] + [pemetrexed disodium]
Product Description
Mechanism of Action
R&D Progress
CBP-501 + [cisplatin]
Product Description
Mechanism of Action
R&D Progress
CBS-9106
Product Description
Mechanism of Action
R&D Progress
CBS-2400
Product Description
Mechanism of Action
R&D Progress
CanBas Co., Ltd. - Pipeline Analysis
CanBas Co., Ltd. - Pipeline Products by Target
CanBas Co., Ltd. - Pipeline Products by Route of Administration
CanBas Co., Ltd. - Pipeline Products by Molecule Type
CanBas Co., Ltd. - Pipeline Products by Mechanism of Action
CanBas Co., Ltd. - Recent Pipeline Updates
CanBas Co., Ltd. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

CanBas Co., Ltd., Key Information
CanBas Co., Ltd., Key Facts
CanBas Co., Ltd. - Pipeline by Indication, 2014
CanBas Co., Ltd. - Pipeline by Stage of Development, 2014
CanBas Co., Ltd. - Monotherapy Products in Pipeline, 2014
CanBas Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014
CanBas Co., Ltd. - Phase II, 2014
CanBas Co., Ltd. - Phase I, 2014
CanBas Co., Ltd. - Preclinical, 2014
CanBas Co., Ltd. - Discovery, 2014
CanBas Co., Ltd. - Pipeline by Target, 2014
CanBas Co., Ltd. - Pipeline by Route of Administration, 2014
CanBas Co., Ltd. - Pipeline by Molecule Type, 2014
CanBas Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
CanBas Co., Ltd. - Recent Pipeline Updates, 2014

LIST OF FIGURES

CanBas Co., Ltd. - Pipeline by Top 10 Indication, 2014
CanBas Co., Ltd. - Pipeline by Stage of Development, 2014
CanBas Co., Ltd. - Monotherapy Products in Pipeline, 2014
CanBas Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014
CanBas Co., Ltd. - Pipeline by Top 10 Target, 2014
CanBas Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
CanBas Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
CanBas Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Skip to top


Ask Your Question

CanBas Co., Ltd. - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: